원문정보
초록
영어
Malaria continues to claim over 2 million people annually and is considered a reemerging fatal disease due to the spread of drug-resistant parasites and insecticide-resistant mosquitoes. Though vaccines have been one of the most cost- effective and easily administered means of controlling infectious diseases, no viable vaccine candidate has been developed for malaria. Glycosylphosphatidylinositol (GPI) anchors are a class of naturally occurring glycolipids that link proteins and glycoproteins via C-terminus to cell membranes. GPI originating from the malarial parasite Plasmodium falciparum has the properties predicted of a toxin, indicating that it is involved in the malarial pathogenesis. The initial efforts demonstrated that anti-GPI antibodies produced against the synthetic GPI glycan, might recognize the native GPI -containing toxin and neutralize proinflammatory activity by P. falciparum, revealing that the synthetic GPI is a prototype carbohydrate anti-toxin vaccine against malaria. In this presentation, a convergent synthesis of a series of oligosaccharides comprised of the malaria GPI glycan, a promising antitoxin malaria vaccine candidate currently in preclinical trials and related deletion sequences as well as a serological study using a GPI glycan microarray will be described.